Universe Pharmaceuticals INC UPC
1.49 USD +0.02 (+1.36%)
At closeNov 3, 2026, 4:00 PM EST
1.51 +0.02 +1.34%
After hours · Nov 3, 4:00 PM ET
1.46 Day range 1.67
1.43 52-week range 17.96
- YTD
- -60.89%
- 1 year
- -67.61%
Financial health
Altman Z-Score
0.61 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 5
Valuation
P/E -0.0×
FY 2018 5y median -0.1× FY 2025
P/S 0.0×
FY 2018 5y median 0.1× FY 2025
P/B 0.0×
FY 2018 5y median 0.1× FY 2025
P/FCF -0.0×
FY 2018 5y median -0.1× FY 2025
EV/EBITDA 8.3×
FY 2018 5y median 2.8× FY 2025
EV/Sales -1.4×
FY 2018 5y median 0.1× FY 2025
FCF Yield -36963.7%
FY 2018 5y median -33.2% FY 2025
Profitability
Gross Margin 35.3%
FY 2018 5y median 35.3% FY 2025
Operating Margin -16.3%
FY 2018 5y median -16.3% FY 2025
Net Margin -20.6%
FY 2018 5y median -20.6% FY 2025
ROE -6.5%
FY 2018 5y median -15.6% FY 2025
ROIC -4.5%
FY 2018 5y median -7.8% FY 2025
ROA -5.3%
FY 2018 5y median -11.6% FY 2025
Growth (YoY)
Revenue -22.4%
FY 2018 FY 2025
Operating Income 63.6%
FY 2018 FY 2025
EPS (diluted) 26.5%
FY 2018 FY 2025
Free Cash Flow 45.3%
FY 2018 FY 2025
Financial Health
Current Ratio 4.1×
FY 2018 5y median 3.2× FY 2025
Quick Ratio 3.9×
FY 2018 5y median 3.0× FY 2025
Debt / Equity 0.2×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 8.3×
FY 2018 5y median 0.3× FY 2025
Interest Coverage -12.6×
FY 2018 5y median -22.5× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-09-30
